BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22447472)

  • 1. New antithrombotic drugs: a revolution in stroke management.
    Bryer A
    Cardiovasc J Afr; 2012 Mar; 23(2):61-2. PubMed ID: 22447472
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk versus benefit of non-vitamin K dependent anticoagulants compared to warfarin for the management of atrial fibrillation in the elderly.
    Ogbonna KC; Jeffery SM
    Drugs Aging; 2013 Jul; 30(7):513-25. PubMed ID: 23591934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New antithrombotic drugs and European approval processes.
    Marijon E; Fauchier L; Le Heuzey JY
    Lancet; 2011 Aug; 378(9792):662-3. PubMed ID: 21856473
    [No Abstract]   [Full Text] [Related]  

  • 4. New antithrombotic drugs for atrial fibrillation: caution is needed.
    Bell S; Nand J; Spriggs D
    Lancet; 2012 Jan; 379(9813):e24; author reply e24-5. PubMed ID: 22284660
    [No Abstract]   [Full Text] [Related]  

  • 5. A new era of antithrombotic therapy in patients with atrial fibrillation.
    Golwala H; Dib C; Tafur A; Abu-Fadel MS
    Am J Med Sci; 2012 Aug; 344(2):128-35. PubMed ID: 22245946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New oral anticoagulant in atrial fibrillation: are they comparable?
    Kalodiki E; Lewis B; Fareed J
    Int Angiol; 2012 Aug; 31(4):307-9. PubMed ID: 22801395
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.
    Harrington AR; Armstrong EP; Nolan PE; Malone DC
    Stroke; 2013 Jun; 44(6):1676-81. PubMed ID: 23549134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New oral anticoagulant agents: the quandary of anticoagulation in the elderly].
    Páramo JA
    Med Clin (Barc); 2013 Oct; 141(8):346-8. PubMed ID: 23831406
    [No Abstract]   [Full Text] [Related]  

  • 9. New alternative anticoagulants in atrial fibrillation: the move beyond warfarin.
    Bhimani AA; Hong M
    Rev Recent Clin Trials; 2013 Jun; 8(2):78-85. PubMed ID: 23859143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Differential therapy with the new anticoagulants, 5].
    Stiefelhagen P
    MMW Fortschr Med; 2013 May; 155(9):20. PubMed ID: 23951642
    [No Abstract]   [Full Text] [Related]  

  • 11. Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal.
    Bauer KA
    Stroke; 2013 Jun; 44(6 Suppl 1):S38-40. PubMed ID: 23709725
    [No Abstract]   [Full Text] [Related]  

  • 12. Anticlotting therapy for atrial fibrillation: should you stay with the devil you know? Preventing stroke with warfarin (Coumadin) can be tricky. New anticlotting drugs can help if you accept certain trade-offs--and take them exactly as directed.
    Harv Mens Health Watch; 2014 Apr; 18(9):1, 7. PubMed ID: 25108916
    [No Abstract]   [Full Text] [Related]  

  • 13. New agents to prevent strokes in nonvalvular atrial fibrillation.
    Putney D; Pratt C
    Methodist Debakey Cardiovasc J; 2012; 8(3):44-6. PubMed ID: 23227289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
    Dumont B; Faille D; Ajzenberg N
    Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
    Schneeweiss S; Gagne JJ; Patrick AR; Choudhry NK; Avorn J
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):480-6. PubMed ID: 22787066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Introduction].
    Valle Bernad R
    Rev Clin Esp; 2012 Jan; 212 Suppl 1():1-2. PubMed ID: 23117645
    [No Abstract]   [Full Text] [Related]  

  • 17. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.
    Miller CS; Grandi SM; Shimony A; Filion KB; Eisenberg MJ
    Am J Cardiol; 2012 Aug; 110(3):453-60. PubMed ID: 22537354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New oral anticoagulants in the management of venous thromboembolism: a major advance?
    Sciascia S; Hunt BJ
    Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):487-8. PubMed ID: 25150440
    [No Abstract]   [Full Text] [Related]  

  • 20. ["Xa-tra-xa": opportunities and open questions about new anticoagulants].
    Beer JH
    Praxis (Bern 1994); 2011 Aug; 100(16):947. PubMed ID: 21910293
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.